Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma.

Iyoda A, Travis WD, Sarkaria IS, Jiang SX, Amano H, Sato Y, Saegusa M, Rusch VW, Satoh Y.

Exp Ther Med. 2011 Nov;2(6):1041-1045.

2.

Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung.

Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, Nishiwaki Y, Ochiai A.

Lung Cancer. 2003 May;40(2):173-80.

PMID:
12711118
3.

Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD.

Am J Pathol. 1996 May;148(5):1531-41.

4.

The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung.

Casali C, Stefani A, Rossi G, Migaldi M, Bettelli S, Parise A, Morandi U.

Ann Thorac Surg. 2004 Jan;77(1):247-52; discussion 252-3.

PMID:
14726070
6.

Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma.

Makino T, Mikami T, Hata Y, Otsuka H, Koezuka S, Isobe K, Tochigi N, Shibuya K, Homma S, Iyoda A.

Ann Thorac Surg. 2016 Nov;102(5):1694-1701. doi: 10.1016/j.athoracsur.2016.04.100.

PMID:
27368130
7.

A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression.

Pelosi G, Scarpa A, Veronesi G, Spaggiari L, Del Curto B, Moore PS, Maisonneuve P, Sonzogni A, Masullo M, Viale G.

Virchows Arch. 2005 Dec;447(6):969-77.

PMID:
16158183
8.

Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma.

Macher-Goeppinger S, Penzel R, Roth W, Dienemann H, Thomas M, Schnabel PA, Schirmacher P, Bläker H.

J Clin Pathol. 2011 Apr;64(4):349-53. doi: 10.1136/jcp.2010.085696.

PMID:
21292787
9.

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF.

Cancer Res. 2005 Mar 1;65(5):1642-6.

10.

The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.

Konishi T, Huang CL, Adachi M, Taki T, Inufusa H, Kodama K, Kohno N, Miyake M.

Int J Oncol. 2000 Mar;16(3):501-11.

PMID:
10675482
11.

Receptor tyrosine kinases in sinonasal undifferentiated carcinomas--evaluation for EGFR, c-KIT, and HER2/neu expression.

Chernock RD, Perry A, Pfeifer JD, Holden JA, Lewis JS Jr.

Head Neck. 2009 Jul;31(7):919-27. doi: 10.1002/hed.21061.

PMID:
19283847
12.

Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.

Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H, Doppman J.

Am J Surg Pathol. 1991 Jun;15(6):529-53.

PMID:
1709558
14.

Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases.

Nagao T, Sugano I, Ishida Y, Tajima Y, Munakata S, Asoh A, Yamazaki K, Muto H, Konno A, Kondo Y, Nagao K.

Mod Pathol. 2000 May;13(5):554-61.

15.

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Review.

PMID:
21531084
16.

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM.

Endocr Relat Cancer. 2010 Jun 25;17(3):623-36. doi: 10.1677/ERC-09-0318.

17.

Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma.

Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T.

Ann Thorac Surg. 2007 Aug;84(2):702-7. Review.

PMID:
17643676
18.

Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report.

Aroldi F, Bertocchi P, Meriggi F, Abeni C, Ogliosi C, Rota L, Zambelli C, Bnà C, Zaniboni A.

Case Rep Oncol. 2014 Jul 16;7(2):478-83. doi: 10.1159/000365413.

19.

Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.

Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H.

Am J Surg Pathol. 1998 May;22(5):526-37.

PMID:
9591721
20.

Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.

Wang X, MacLennan GT, Zhang S, Montironi R, Lopez-Beltran A, Tan PH, Foster S, Baldridge LA, Cheng L.

Hum Pathol. 2009 Feb;40(2):211-7. doi: 10.1016/j.humpath.2008.07.003.

PMID:
18799188
Items per page

Supplemental Content

Support Center